The latest price target for Alnylam Pharmaceuticals (NASDAQ:ALNY) was reported by RBC Capital on January 21, 2025. The analyst firm set a price target for $300.00 expecting ALNY to rise to within 12 months (a possible 13.21% upside). 81 analyst firms have reported ratings in the last year.

The latest analyst rating for Alnylam Pharmaceuticals (NASDAQ:ALNY) was provided by RBC Capital, and Alnylam Pharmaceuticals reiterated their outperform rating.

The last upgrade for Alnylam Pharmaceuticals Inc happened on August 16, 2024 when Goldman Sachs raised their price target to $370. Goldman Sachs previously had a neutral for Alnylam Pharmaceuticals Inc.

The last downgrade for Alnylam Pharmaceuticals Inc happened on November 12, 2024 when Wolfe Research changed their price target from N/A to N/A for Alnylam Pharmaceuticals Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Alnylam Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Alnylam Pharmaceuticals was filed on January 21, 2025 so you should expect the next rating to be made available sometime around January 21, 2026.

While ratings are subjective and will change, the latest Alnylam Pharmaceuticals (ALNY) rating was a reiterated with a price target of $300.00 to $300.00. The current price Alnylam Pharmaceuticals (ALNY) is trading at is $264.99, which is out of the analyst’s predicted range.